BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05191667 (AN0025 and Chemoradiotherapy in Esophageal Cancer): BVCT ex-ante prediction vs. reported outcome

On 19 Oct 2023, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 23 May 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05191667
Drug Name
AN0025 and Chemoradiotherapy
Drug MoA
PGE2 EP4 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Esophageal Cancer
Human Patients
32
Sponsor
Adlai Nortye
Phase
Phase 1

Prediction of , index 1292

Prospective Prediction
Prediction Index
1292
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit)
Technical Prediction
FAILURE (statistically insignificant additive clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
217 days in advance
Readout Data Interpretation
50% ORR (6/12) vs 63.5% ORR (1L tislelizumab + chemo; 68-88% ORR for CRT alone doi- 10.3390/cancers15010010).
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Chemoradiotherapy in Patients With Locally Advanced/Locally Recurrent Esophageal Cancer
Phase
Phase 1
Status
Suspended
Enrollment
32
Lead sponsor
Adlai Nortye Biopharma Co., Ltd.
Conditions
Esophageal Cancer
Interventions
DRUG: AN0025
Design
Single group · None
Primary purpose
Treatment
Start
2022-01-18
Primary completion
2025-12
Completion
2025-12
Primary outcomes
  • Number of participants with Dose Limiting Toxicities (DLTs) (4 weeks)

NCT05191667 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials